

## **Copyright Notice**

CPT codes, descriptions and other data only are copyright 2023 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply. Fee schedules, relative value units, conversion factors and/or related components aren't assigned by the AMA, aren't part of CPT, and the AMA isn't recommending their use. The AMA doesn't directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

# Coverage & Billing Information for the 2023 Quarterly Code Update

## BACKGROUND

Iowa Medicaid has reviewed the **Q4 2023** Billing Code Update to determine coverage and billing guidelines. The Iowa Medicaid coverage and billing information provided in this bulletin is effective **October 1, 2023**. This bulletin serves as a notice of the following information:

### Table 1

- New Current Procedural Terminology (CPT<sup>®</sup>) and Healthcare Common Procedure Coding System (HCPCS) codes included in the Q1 2023 code update. Coverage and billing information for these codes applies to dates of service on or after **October 1, 2023**.

### Table 2

- New Current Dental Terminology (CDT<sup>®</sup>) codes included in the Q1 2023 code update. Coverage and billing information for these codes applies to dates of service on or after **N/A**.

### Table 3

- International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes. Coverage and billing for these codes applies to dates of service on or after **October 1, 2023**.

### Table 4

- International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) codes. Coverage and billing for these codes applies to dates of service on or after **October 1, 2023**.

### Table 5

- Modifiers included in the code update. Coverage and billing information for these codes applies to dates of service on or after **N/A**.

### Table 6

- CPT<sup>®</sup>, CDT<sup>®</sup>, & HCPCS codes that would be considered Outpatient Hospital on or after **October 1, 2023**.

### Table 7

- Non-Covered Codes - CPT<sup>®</sup>, CDT<sup>®</sup>, HCPCS, ICD-10-CM & ICD-10-PCS codes that have been thoroughly reviewed and Iowa Medicaid has decided not to cover effective **October 1, 2023**.

### Table 8

- Deleted Codes - CPT<sup>®</sup>, CDT<sup>®</sup>, HCPCS, ICD-10-CM & ICD-10-PCS codes that have been discontinued effective **September 30, 2023**.

Managed Care Organization (MCOs) establish and publish reimbursement, PA, and billing information within the managed care delivery system. Questions about managed care PA should be directed to the MCP with which the member is enrolled.

**Iowa Medicaid Provider Services:**

- Phone: 1-800-338-7909
- Email: [imeproviderservices@dhs.state.ia.us](mailto:imeproviderservices@dhs.state.ia.us)

**Wellpoint Iowa, Inc.:**

- Phone: 1-833-731-2143
- Email: [ProviderSolutionsIA@wellpoint.com](mailto:ProviderSolutionsIA@wellpoint.com)
- Website: <https://www.provider.wellpoint.com/iowa-provider/home>

**Iowa Total Care:**

- Phone: 1-833-404-1061
- Email: [providerrelations@iowatotalcare.com](mailto:providerrelations@iowatotalcare.com)
- Website: <https://www.iowatotalcare.com>

**Molina Healthcare of Iowa:**

- Phone: 1-844-236-1464
- Email: [iaproviderrelations@molinahealthcare.com](mailto:iaproviderrelations@molinahealthcare.com)
- Website: <https://www.molinahealthcare.com/providers/ia/medicaid/home.aspx>
- Provider portal: <https://www.availity.com/molinahealthcare>

The **Q4 2023** code update may include modifications to descriptions for some existing HCPCS/CPT codes. These modifications are available for reference or download from the CMS website at [www.cms.gov](http://www.cms.gov).

The **Q4** code update also includes a list of deleted codes. These codes are available for reference or download from the CMS website at [cms.gov](http://cms.gov). If there is a replacement code, Iowa Medicaid has added the replacement code for which there were deleted codes effective as of **September 30, 2023**.

**Special Billing Information** in Table I shows if the code requires a Prior Authorization or if it suspends for claim review. If the column is blank, there is no special billing information.

Iowa Medicaid will update the fee schedule as rates become available.

**Table 1 – CPT® & HCPCS Codes**

[Back to top](#)

Code	Description	Effective Date	Special Billing Information
<b>0408U</b>	Infectious agent antigen detection by bulk acoustic wave biosensor immunoassay, severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19])	10/1/2023	
<b>A9573</b>	Injection, gadopiclesol, 1 ml	10/1/2023	
<b>A9603</b>	Injection, pafolacianine, 0.1 mg	10/1/2023	
<b>A9697</b>	Injection, carboxydextran-coated superparamagnetic iron oxide, per study dose	10/1/2023	
<b>B4148</b>	Enteral feeding supply kit; elastomeric control fed, per day, includes but not limited to feeding/flushing syringe, administration set tubing, dressings, tape	10/1/2023	
<b>C9152</b>	Injection, aripiprazole, (abilify asimtufii), 1 mg	10/1/2023	
<b>C9153</b>	Injection, amisulpride, 1 mg	10/1/2023	
<b>C9154</b>	Injection, buprenorphine extended-release (brixadi), 1 mg	10/1/2023	
<b>C9155</b>	Injection, epcoritamab-bysp, 0.16 mg	10/1/2023	PA Required
<b>C9156</b>	Flotufolastat f 18, diagnostic, 1 millicurie	10/1/2023	
<b>C9157</b>	Injection, tofersen, 1 mg	10/1/2023	PA Required
<b>C9158</b>	Injection, risperidone, (uzedy), 1 mg	10/1/2023	
<b>C9791</b>	Magnetic resonance imaging with inhaled hyperpolarized xenon-129 contrast agent, chest, including preparation and administration of agent	10/1/2023	PA Required
<b>J0349</b>	Injection, rezafungin, 1 mg	10/1/2023	PA Required
<b>J0801</b>	Injection, corticotropin (acthar gel), up to 40 units	10/1/2023	
<b>J0802</b>	Injection, corticotropin (ani), up to 40 units	10/1/2023	
<b>J0874</b>	Injection, daptomycin (baxter), not therapeutically equivalent to j0878, 1 mg	10/1/2023	
<b>J0889</b>	Daprodustat, oral, 1 mg, (for esrd on dialysis)	10/1/2023	
<b>J2359</b>	Injection, olanzapine, 0.5 mg	10/1/2023	
<b>J2781</b>	Injection, pegcetacoplan, intravitreal, 1 mg	10/1/2023	PA Required
<b>J7214</b>	Injection, factor viii/von willebrand factor complex, recombinant (altuviio), per factor viii i.u.	10/1/2023	
<b>J7519</b>	Injection, mycophenolate mofetil, 10 mg	10/1/2023	
<b>J9064</b>	Injection, cabazitaxel (sandoz), not therapeutically equivalent to j9043, 1 mg	10/1/2023	
<b>J9345</b>	Injection, retifanlimab-dlwr, 1 mg	10/1/2023	PA Required
<b>L1681</b>	Hip orthosis, bil hip joints and thigh cuffs, adjustable flexion, extension, abduction control of hip joint, postop hip abd type, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized	10/1/2023	

\*Covid Related Code

[Back to top](#)

Table 2 – CDT©

[Back to top](#)

Code	Description	Effective Date
N/A	N/A	N/A

Table 3 – ICD-10-CM Codes

[Back to top](#)

Code	Description	Effective Date
<b>A41.54</b>	Sepsis due to Acinetobacter baumannii	10/1/2023
<b>B96.83</b>	Acinetobacter baumannii as the cause of diseases classified elsewhere	10/1/2023
<b>D13.91</b>	Familial adenomatous polyposis	10/1/2023
<b>D13.99</b>	Benign neoplasm of ill-defined sites within the digestive system	10/1/2023
<b>D48.110</b>	Desmoid tumor of head and neck	10/1/2023
<b>D48.111</b>	Desmoid tumor of chest wall	10/1/2023
<b>D48.112</b>	Desmoid tumor, intrathoracic	10/1/2023
<b>D48.113</b>	Desmoid tumor of abdominal wall	10/1/2023
<b>D48.114</b>	Desmoid tumor, intraabdominal	10/1/2023
<b>D48.115</b>	Desmoid tumor of upper extremity and shoulder girdle	10/1/2023
<b>D48.116</b>	Desmoid tumor of lower extremity and pelvic girdle	10/1/2023
<b>D48.117</b>	Desmoid tumor of back	10/1/2023
<b>D48.118</b>	Desmoid tumor of other site	10/1/2023
<b>D48.119</b>	Desmoid tumor of unspecified site	10/1/2023
<b>D48.19</b>	Other specified neoplasm of uncertain behavior of connective and other soft tissue	10/1/2023
<b>D57.04</b>	Hb-SS disease with dactylitis	10/1/2023
<b>D57.214</b>	Sickle-cell/Hb-C disease with dactylitis	10/1/2023
<b>D57.414</b>	Sickle-cell thalassemia, unspecified, with dactylitis	10/1/2023
<b>D57.434</b>	Sickle-cell thalassemia beta zero with dactylitis	10/1/2023
<b>D57.454</b>	Sickle-cell thalassemia beta plus with dactylitis	10/1/2023
<b>D57.814</b>	Other sickle-cell disorders with dactylitis	10/1/2023
<b>D61.02</b>	Shwachman-Diamond syndrome	10/1/2023
<b>D89.84</b>	IgG4-related disease	10/1/2023
<b>E20.810</b>	Autosomal dominant hypocalcemia	10/1/2023
<b>E20.811</b>	Secondary hypoparathyroidism in diseases classified elsewhere	10/1/2023
<b>E20.812</b>	Autoimmune hypoparathyroidism	10/1/2023
<b>E20.818</b>	Other specified hypoparathyroidism due to impaired parathyroid hormone secretion	10/1/2023
<b>E20.819</b>	Hypoparathyroidism due to impaired parathyroid hormone secretion, unspecified	10/1/2023
<b>E20.89</b>	Other specified hypoparathyroidism	10/1/2023

## SERVICES

<b>E74.05</b>	Lysosome-associated membrane protein 2 [LAMP2] deficiency	10/1/2023
<b>E75.27</b>	Pelizaeus-Merzbacher disease	10/1/2023
<b>E75.28</b>	Canavan disease	10/1/2023
<b>E79.81</b>	Aicardi-Goutières syndrome	10/1/2023
<b>E79.82</b>	Hereditary xanthinuria	10/1/2023
<b>E79.89</b>	Other specified disorders of purine and pyrimidine metabolism	10/1/2023
<b>E88.43</b>	Disorders of mitochondrial tRNA synthetases	10/1/2023
<b>E88.810</b>	Metabolic syndrome	10/1/2023
<b>E88.811</b>	Insulin resistance syndrome, Type A	10/1/2023
<b>E88.818</b>	Other insulin resistance	10/1/2023
<b>E88.819</b>	Insulin resistance, unspecified	10/1/2023
<b>E88.A</b>	Wasting disease (syndrome) due to underlying condition	10/1/2023
<b>G11.5</b>	Hypomyelination - hypogonadotropic hypogonadism - hypodontia	10/1/2023
<b>G11.6</b>	Leukodystrophy with vanishing white matter disease	10/1/2023
<b>G20.A1</b>	Parkinson's disease without dyskinesia, without mention of fluctuations	10/1/2023
<b>G20.A2</b>	Parkinson's disease without dyskinesia, with fluctuations	10/1/2023
<b>G20.B1</b>	Parkinson's disease with dyskinesia, without mention of fluctuations	10/1/2023
<b>G20.B2</b>	Parkinson's disease with dyskinesia, with fluctuations	10/1/2023
<b>G20.C</b>	Parkinsonism, unspecified	10/1/2023
<b>G23.3</b>	Hypomyelination with atrophy of the basal ganglia and cerebellum	10/1/2023
<b>G31.80</b>	Leukodystrophy, unspecified	10/1/2023
<b>G31.86</b>	Alexander disease	10/1/2023
<b>G37.81</b>	Myelin oligodendrocyte glycoprotein antibody disease	10/1/2023
<b>G37.89</b>	Other specified demyelinating diseases of central nervous system	10/1/2023
<b>G40.C01</b>	Lafora progressive myoclonus epilepsy, not intractable, with status epilepticus	10/1/2023
<b>G40.C09</b>	Lafora progressive myoclonus epilepsy, not intractable, without status epilepticus	10/1/2023
<b>G40.C11</b>	Lafora progressive myoclonus epilepsy, intractable, with status epilepticus	10/1/2023
<b>G40.C19</b>	Lafora progressive myoclonus epilepsy, intractable, without status epilepticus	10/1/2023
<b>G43.E01</b>	Chronic migraine with aura, not intractable, with status migrainosus	10/1/2023
<b>G43.E09</b>	Chronic migraine with aura, not intractable, without status migrainosus	10/1/2023
<b>G43.E11</b>	Chronic migraine with aura, intractable, with status migrainosus	10/1/2023
<b>G43.E19</b>	Chronic migraine with aura, intractable, without status migrainosus	10/1/2023
<b>G90.B</b>	LMNBI-related autosomal dominant leukodystrophy	10/1/2023
<b>G93.42</b>	Megaloencephalic leukoencephalopathy with subcortical cysts	10/1/2023
<b>G93.43</b>	Leukoencephalopathy with calcifications and cysts	10/1/2023

## SERVICES

<b>G93.44</b>	Adult-onset leukodystrophy with axonal spheroids	10/1/2023
<b>H36.811</b>	Nonproliferative sickle-cell retinopathy, right eye	10/1/2023
<b>H36.812</b>	Nonproliferative sickle-cell retinopathy, left eye	10/1/2023
<b>H36.813</b>	Nonproliferative sickle-cell retinopathy, bilateral	10/1/2023
<b>H36.819</b>	Nonproliferative sickle-cell retinopathy, unspecified eye	10/1/2023
<b>H36.821</b>	Proliferative sickle-cell retinopathy, right eye	10/1/2023
<b>H36.822</b>	Proliferative sickle-cell retinopathy, left eye	10/1/2023
<b>H36.823</b>	Proliferative sickle-cell retinopathy, bilateral	10/1/2023
<b>H36.829</b>	Proliferative sickle-cell retinopathy, unspecified eye	10/1/2023
<b>H36.89</b>	Other retinal disorders in diseases classified elsewhere	10/1/2023
<b>H50.621</b>	Inferior oblique muscle entrapment, right eye	10/1/2023
<b>H50.622</b>	Inferior oblique muscle entrapment, left eye	10/1/2023
<b>H50.629</b>	Inferior oblique muscle entrapment, unspecified eye	10/1/2023
<b>H50.631</b>	Inferior rectus muscle entrapment, right eye	10/1/2023
<b>H50.632</b>	Inferior rectus muscle entrapment, left eye	10/1/2023
<b>H50.639</b>	Inferior rectus muscle entrapment, unspecified eye	10/1/2023
<b>H50.641</b>	Lateral rectus muscle entrapment, right eye	10/1/2023
<b>H50.642</b>	Lateral rectus muscle entrapment, left eye	10/1/2023
<b>H50.649</b>	Lateral rectus muscle entrapment, unspecified eye	10/1/2023
<b>H50.651</b>	Medial rectus muscle entrapment, right eye	10/1/2023
<b>H50.652</b>	Medial rectus muscle entrapment, left eye	10/1/2023
<b>H50.659</b>	Medial rectus muscle entrapment, unspecified eye	10/1/2023
<b>H50.661</b>	Superior oblique muscle entrapment, right eye	10/1/2023
<b>H50.662</b>	Superior oblique muscle entrapment, left eye	10/1/2023
<b>H50.669</b>	Superior oblique muscle entrapment, unspecified eye	10/1/2023
<b>H50.671</b>	Superior rectus muscle entrapment, right eye	10/1/2023
<b>H50.672</b>	Superior rectus muscle entrapment, left eye	10/1/2023
<b>H50.679</b>	Superior rectus muscle entrapment, unspecified eye	10/1/2023
<b>H50.681</b>	Extraocular muscle entrapment, unspecified, right eye	10/1/2023
<b>H50.682</b>	Extraocular muscle entrapment, unspecified, left eye	10/1/2023
<b>H50.689</b>	Extraocular muscle entrapment, unspecified, unspecified eye	10/1/2023
<b>H57.8A1</b>	Foreign body sensation, right eye	10/1/2023
<b>H57.8A2</b>	Foreign body sensation, left eye	10/1/2023
<b>H57.8A3</b>	Foreign body sensation, bilateral eyes	10/1/2023
<b>H57.8A9</b>	Foreign body sensation, unspecified eye	10/1/2023

## SERVICES

<b>I1A.0</b>	Resistant hypertension	10/1/2023
<b>I20.81</b>	Angina pectoris with coronary microvascular dysfunction	10/1/2023
<b>I20.89</b>	Other forms of angina pectoris	10/1/2023
<b>I21.B</b>	Myocardial infarction with coronary microvascular dysfunction	10/1/2023
<b>I24.81</b>	Acute coronary microvascular dysfunction	10/1/2023
<b>I24.89</b>	Other forms of acute ischemic heart disease	10/1/2023
<b>I25.85</b>	Chronic coronary microvascular dysfunction	10/1/2023
<b>I47.10</b>	Supraventricular tachycardia, unspecified	10/1/2023
<b>I47.11</b>	Inappropriate sinus tachycardia, so stated	10/1/2023
<b>I47.19</b>	Other supraventricular tachycardia	10/1/2023
<b>J15.61</b>	Pneumonia due to <i>Acinetobacter baumannii</i>	10/1/2023
<b>J15.69</b>	Pneumonia due to other Gram-negative bacteria	10/1/2023
<b>J44.81</b>	Bronchiolitis obliterans and bronchiolitis obliterans syndrome	10/1/2023
<b>J44.89</b>	Other specified chronic obstructive pulmonary disease	10/1/2023
<b>J4A.0</b>	Restrictive allograft syndrome	10/1/2023
<b>J4A.8</b>	Other chronic lung allograft dysfunction	10/1/2023
<b>J4A.9</b>	Chronic lung allograft dysfunction, unspecified	10/1/2023
<b>K35.200</b>	Acute appendicitis with generalized peritonitis, without perforation or abscess	10/1/2023
<b>K35.201</b>	Acute appendicitis with generalized peritonitis, with perforation, without abscess	10/1/2023
<b>K35.209</b>	Acute appendicitis with generalized peritonitis, without abscess, unspecified as to perforation	10/1/2023
<b>K35.210</b>	Acute appendicitis with generalized peritonitis, without perforation, with abscess	10/1/2023
<b>K35.211</b>	Acute appendicitis with generalized peritonitis, with perforation and abscess	10/1/2023
<b>K35.219</b>	Acute appendicitis with generalized peritonitis, with abscess, unspecified as to perforation	10/1/2023
<b>K63.8211</b>	Small intestinal bacterial overgrowth, hydrogen-subtype	10/1/2023
<b>K63.8212</b>	Small intestinal bacterial overgrowth, hydrogen sulfide-subtype	10/1/2023
<b>K63.8219</b>	Small intestinal bacterial overgrowth, unspecified	10/1/2023
<b>K63.822</b>	Small intestinal fungal overgrowth	10/1/2023
<b>K63.829</b>	Intestinal methanogen overgrowth, unspecified	10/1/2023
<b>K68.2</b>	Retroperitoneal fibrosis	10/1/2023
<b>K68.3</b>	Retroperitoneal hematoma	10/1/2023
<b>K90.821</b>	Short bowel syndrome with colon in continuity	10/1/2023
<b>K90.822</b>	Short bowel syndrome without colon in continuity	10/1/2023
<b>K90.829</b>	Short bowel syndrome, unspecified	10/1/2023
<b>K90.83</b>	Intestinal failure	10/1/2023
<b>M80.0B1A</b>	Age-related osteoporosis with current pathological fracture, right pelvis, initial encounter for fracture	10/1/2023



## SERVICES

<b>M80.0B1D</b>	Age-related osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with routine healing	10/1/2023
<b>M80.0B1G</b>	Age-related osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with delayed healing	10/1/2023
<b>M80.0B1K</b>	Age-related osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with nonunion	10/1/2023
<b>M80.0B1P</b>	Age-related osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with malunion	10/1/2023
<b>M80.0B1S</b>	Age-related osteoporosis with current pathological fracture, right pelvis, sequela	10/1/2023
<b>M80.0B2A</b>	Age-related osteoporosis with current pathological fracture, left pelvis, initial encounter for fracture	10/1/2023
<b>M80.0B2D</b>	Age-related osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with routine healing	10/1/2023
<b>M80.0B2G</b>	Age-related osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with delayed healing	10/1/2023
<b>M80.0B2K</b>	Age-related osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with nonunion	10/1/2023
<b>M80.0B2P</b>	Age-related osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with malunion	10/1/2023
<b>M80.0B2S</b>	Age-related osteoporosis with current pathological fracture, left pelvis, sequela	10/1/2023
<b>M80.0B9A</b>	Age-related osteoporosis with current pathological fracture, unspecified pelvis, initial encounter for fracture	10/1/2023
<b>M80.0B9D</b>	Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with routine healing	10/1/2023
<b>M80.0B9G</b>	Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with delayed healing	10/1/2023
<b>M80.0B9K</b>	Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with nonunion	10/1/2023
<b>M80.0B9P</b>	Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with malunion	10/1/2023
<b>M80.0B9S</b>	Age-related osteoporosis with current pathological fracture, unspecified pelvis, sequela	10/1/2023
<b>M80.8B1A</b>	Other osteoporosis with current pathological fracture, right pelvis, initial encounter for fracture	10/1/2023
<b>M80.8B1D</b>	Other osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with routine healing	10/1/2023
<b>M80.8B1G</b>	Other osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with delayed healing	10/1/2023

## SERVICES

<b>M80.8B1K</b>	Other osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with nonunion	10/1/2023
<b>M80.8B1P</b>	Other osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with malunion	10/1/2023
<b>M80.8B1S</b>	Other osteoporosis with current pathological fracture, right pelvis, sequela	10/1/2023
<b>M80.8B2A</b>	Other osteoporosis with current pathological fracture, left pelvis, initial encounter for fracture	10/1/2023
<b>M80.8B2D</b>	Other osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with routine healing	10/1/2023
<b>M80.8B2G</b>	Other osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with delayed healing	10/1/2023
<b>M80.8B2K</b>	Other osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with nonunion	10/1/2023
<b>M80.8B2P</b>	Other osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with malunion	10/1/2023
<b>M80.8B2S</b>	Other osteoporosis with current pathological fracture, left pelvis, sequela	10/1/2023
<b>M80.8B9A</b>	Other osteoporosis with current pathological fracture, unspecified pelvis, initial encounter for fracture	10/1/2023
<b>M80.8B9D</b>	Other osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with routine healing	10/1/2023
<b>M80.8B9G</b>	Other osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with delayed healing	10/1/2023
<b>M80.8B9K</b>	Other osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with nonunion	10/1/2023
<b>M80.8B9P</b>	Other osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with malunion	10/1/2023
<b>M80.8B9S</b>	Other osteoporosis with current pathological fracture, unspecified pelvis, sequela	10/1/2023
<b>N02.B1</b>	Recurrent and persistent immunoglobulin A nephropathy with glomerular lesion	10/1/2023
<b>N02.B2</b>	Recurrent and persistent immunoglobulin A nephropathy with focal and segmental glomerular lesion	10/1/2023
<b>N02.B3</b>	Recurrent and persistent immunoglobulin A nephropathy with diffuse membranoproliferative glomerulonephritis	10/1/2023
<b>N02.B4</b>	Recurrent and persistent immunoglobulin A nephropathy with diffuse membranous glomerulonephritis	10/1/2023
<b>N02.B5</b>	Recurrent and persistent immunoglobulin A nephropathy with diffuse mesangial proliferative glomerulonephritis	10/1/2023
<b>N02.B6</b>	Recurrent and persistent immunoglobulin A nephropathy with diffuse mesangiocapillary glomerulonephritis	10/1/2023
<b>N02.B9</b>	Other recurrent and persistent immunoglobulin A nephropathy	10/1/2023
<b>N04.20</b>	Nephrotic syndrome with diffuse membranous glomerulonephritis, unspecified	10/1/2023
<b>N04.21</b>	Primary membranous nephropathy with nephrotic syndrome	10/1/2023
<b>N04.22</b>	Secondary membranous nephropathy with nephrotic syndrome	10/1/2023
<b>N04.29</b>	Other nephrotic syndrome with diffuse membranous glomerulonephritis	10/1/2023
<b>N06.20</b>	Isolated proteinuria with diffuse membranous glomerulonephritis, unspecified	10/1/2023

## SERVICES

<b>N06.21</b>	Primary membranous nephropathy with isolated proteinuria	10/1/2023
<b>N06.22</b>	Secondary membranous nephropathy with isolated proteinuria	10/1/2023
<b>N06.29</b>	Other isolated proteinuria with diffuse membranous glomerulonephritis	10/1/2023
<b>O26.641</b>	Intrahepatic cholestasis of pregnancy, first trimester	10/1/2023
<b>O26.642</b>	Intrahepatic cholestasis of pregnancy, second trimester	10/1/2023
<b>O26.643</b>	Intrahepatic cholestasis of pregnancy, third trimester	10/1/2023
<b>O26.649</b>	Intrahepatic cholestasis of pregnancy, unspecified trimester	10/1/2023
<b>O90.41</b>	Hepatorenal syndrome following labor and delivery	10/1/2023
<b>O90.49</b>	Other postpartum acute kidney failure	10/1/2023
<b>Q44.70</b>	Other congenital malformation of liver, unspecified	10/1/2023
<b>Q44.71</b>	Alagille syndrome	10/1/2023
<b>Q44.79</b>	Other congenital malformations of liver	10/1/2023
<b>Q75.001</b>	Craniosynostosis unspecified, unilateral	10/1/2023
<b>Q75.002</b>	Craniosynostosis unspecified, bilateral	10/1/2023
<b>Q75.009</b>	Craniosynostosis unspecified	10/1/2023
<b>Q75.01</b>	Sagittal craniosynostosis	10/1/2023
<b>Q75.021</b>	Coronal craniosynostosis unilateral	10/1/2023
<b>Q75.022</b>	Coronal craniosynostosis bilateral	10/1/2023
<b>Q75.029</b>	Coronal craniosynostosis unspecified	10/1/2023
<b>Q75.03</b>	Metopic craniosynostosis	10/1/2023
<b>Q75.041</b>	Lambdoid craniosynostosis, unilateral	10/1/2023
<b>Q75.042</b>	Lambdoid craniosynostosis, bilateral	10/1/2023
<b>Q75.049</b>	Lambdoid craniosynostosis, unspecified	10/1/2023
<b>Q75.051</b>	Cloverleaf skull	10/1/2023
<b>Q75.052</b>	Pansynostosis	10/1/2023
<b>Q75.058</b>	Other multi-suture craniosynostosis	10/1/2023
<b>Q75.08</b>	Other single-suture craniosynostosis	10/1/2023
<b>Q87.83</b>	Bardet-Biedl syndrome	10/1/2023
<b>Q87.84</b>	Laurence-Moon syndrome	10/1/2023
<b>Q87.85</b>	MED13L syndrome	10/1/2023
<b>Q93.52</b>	Phelan-McDermid syndrome	10/1/2023
<b>R09.A0</b>	Foreign body sensation, unspecified	10/1/2023
<b>R09.A1</b>	Foreign body sensation, nose	10/1/2023
<b>R09.A2</b>	Foreign body sensation, throat	10/1/2023
<b>R09.A9</b>	Foreign body sensation, other site	10/1/2023

## SERVICES

<b>R40.2A</b>	Nontraumatic coma due to underlying condition	10/1/2023
<b>R92.30</b>	Dense breasts, unspecified	10/1/2023
<b>R92.311</b>	Mammographic fatty tissue density, right breast	10/1/2023
<b>R92.312</b>	Mammographic fatty tissue density, left breast	10/1/2023
<b>R92.313</b>	Mammographic fatty tissue density, bilateral breasts	10/1/2023
<b>R92.321</b>	Mammographic fibroglandular density, right breast	10/1/2023
<b>R92.322</b>	Mammographic fibroglandular density, left breast	10/1/2023
<b>R92.323</b>	Mammographic fibroglandular density, bilateral breasts	10/1/2023
<b>R92.331</b>	Mammographic heterogeneous density, right breast	10/1/2023
<b>R92.332</b>	Mammographic heterogeneous density, left breast	10/1/2023
<b>R92.333</b>	Mammographic heterogeneous density, bilateral breasts	10/1/2023
<b>R92.341</b>	Mammographic extreme density, right breast	10/1/2023
<b>R92.342</b>	Mammographic extreme density, left breast	10/1/2023
<b>R92.343</b>	Mammographic extreme density, bilateral breasts	10/1/2023
<b>T56.821A</b>	Toxic effect of gadolinium, accidental (unintentional), initial encounter	10/1/2023
<b>T56.821D</b>	Toxic effect of gadolinium, accidental (unintentional), subsequent encounter	10/1/2023
<b>T56.821S</b>	Toxic effect of gadolinium, accidental (unintentional), sequela	10/1/2023
<b>T56.822A</b>	Toxic effect of gadolinium, intentional self-harm, initial encounter	10/1/2023
<b>T56.822D</b>	Toxic effect of gadolinium, intentional self-harm, subsequent encounter	10/1/2023
<b>T56.822S</b>	Toxic effect of gadolinium, intentional self-harm, sequela	10/1/2023
<b>T56.823A</b>	Toxic effect of gadolinium, assault, initial encounter	10/1/2023
<b>T56.823D</b>	Toxic effect of gadolinium, assault, subsequent encounter	10/1/2023
<b>T56.823S</b>	Toxic effect of gadolinium, assault, sequela	10/1/2023
<b>T56.824A</b>	Toxic effect of gadolinium, undetermined, initial encounter	10/1/2023
<b>T56.824D</b>	Toxic effect of gadolinium, undetermined, subsequent encounter	10/1/2023
<b>T56.824S</b>	Toxic effect of gadolinium, undetermined, sequela	10/1/2023
<b>W44.8XXA</b>	Other foreign body entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.8XXD</b>	Other foreign body entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.8XXS</b>	Other foreign body entering into or through a natural orifice, sequela	10/1/2023
<b>W44.9XXA</b>	Unspecified foreign body entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.9XXD</b>	Unspecified foreign body entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.9XXS</b>	Unspecified foreign body entering into or through a natural orifice, sequela	10/1/2023
<b>W44.A0XA</b>	Battery unspecified, entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.A0XD</b>	Battery unspecified, entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.A0XS</b>	Battery unspecified, entering into or through a natural orifice, sequela	10/1/2023

## SERVICES

<b>W44.A1XA</b>	Button battery entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.A1XD</b>	Button battery entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.A1XS</b>	Button battery entering into or through a natural orifice, sequela	10/1/2023
<b>W44.A9XA</b>	Other batteries entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.A9XD</b>	Other batteries entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.A9XS</b>	Other batteries entering into or through a natural orifice, sequela	10/1/2023
<b>W44.B0XA</b>	Plastic object unspecified, entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.B0XD</b>	Plastic object unspecified, entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.B0XS</b>	Plastic object unspecified, entering into or through a natural orifice, sequela	10/1/2023
<b>W44.B1XA</b>	Plastic bead entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.B1XD</b>	Plastic bead entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.B1XS</b>	Plastic bead entering into or through a natural orifice, sequela	10/1/2023
<b>W44.B2XA</b>	Plastic coin entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.B2XD</b>	Plastic coin entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.B2XS</b>	Plastic coin entering into or through a natural orifice, sequela	10/1/2023
<b>W44.B3XA</b>	Plastic toy and toy part entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.B3XD</b>	Plastic toy and toy part entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.B3XS</b>	Plastic toy and toy part entering into or through a natural orifice, sequela	10/1/2023
<b>W44.B4XA</b>	Plastic jewelry entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.B4XD</b>	Plastic jewelry entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.B4XS</b>	Plastic jewelry entering into or through a natural orifice, sequela	10/1/2023
<b>W44.B5XA</b>	Plastic bottle entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.B5XD</b>	Plastic bottle entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.B5XS</b>	Plastic bottle entering into or through a natural orifice, sequela	10/1/2023
<b>W44.B9XA</b>	Other plastic object entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.B9XD</b>	Other plastic object entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.B9XS</b>	Other plastic object entering into or through a natural orifice, sequela	10/1/2023
<b>W44.C0XA</b>	Glass unspecified, entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.C0XD</b>	Glass unspecified, entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.C0XS</b>	Glass unspecified, entering into or through a natural orifice, sequela	10/1/2023
<b>W44.C1XA</b>	Sharp glass entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.C1XD</b>	Sharp glass entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.C1XS</b>	Sharp glass entering into or through a natural orifice, sequela	10/1/2023
<b>W44.C2XA</b>	Intact glass entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.C2XD</b>	Intact glass entering into or through a natural orifice, subsequent encounter	10/1/2023

## SERVICES

<b>W44.C2XS</b>	Intact glass entering into or through a natural orifice, sequela	10/1/2023
<b>W44.D0XA</b>	Magnetic metal object unspecified, entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.D0XD</b>	Magnetic metal object unspecified, entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.D0XS</b>	Magnetic metal object unspecified, entering into or through a natural orifice, sequela	10/1/2023
<b>W44.D1XA</b>	Magnetic metal bead entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.D1XD</b>	Magnetic metal bead entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.D1XS</b>	Magnetic metal bead entering into or through a natural orifice, sequela	10/1/2023
<b>W44.D2XA</b>	Magnetic metal coin entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.D2XD</b>	Magnetic metal coin entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.D2XS</b>	Magnetic metal coin entering into or through a natural orifice, sequela	10/1/2023
<b>W44.D3XA</b>	Magnetic metal toy entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.D3XD</b>	Magnetic metal toy entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.D3XS</b>	Magnetic metal toy entering into or through a natural orifice, sequela	10/1/2023
<b>W44.D4XA</b>	Magnetic metal jewelry entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.D4XD</b>	Magnetic metal jewelry entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.D4XS</b>	Magnetic metal jewelry entering into or through a natural orifice, sequela	10/1/2023
<b>W44.D9XA</b>	Other magnetic metal objects entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.D9XD</b>	Other magnetic metal objects entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.D9XS</b>	Other magnetic metal objects entering into or through a natural orifice, sequela	10/1/2023
<b>W44.E0XA</b>	Non-magnetic metal object unspecified, entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.E0XD</b>	Non-magnetic metal object unspecified, entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.E0XS</b>	Non-magnetic metal object unspecified, entering into or through a natural orifice, sequela	10/1/2023
<b>W44.E1XA</b>	Non-magnetic metal bead entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.E1XD</b>	Non-magnetic metal bead entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.E1XS</b>	Non-magnetic metal bead entering into or through a natural orifice, sequela	10/1/2023
<b>W44.E2XA</b>	Non-magnetic metal coin entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.E2XD</b>	Non-magnetic metal coin entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.E2XS</b>	Non-magnetic metal coin entering into or through a natural orifice, sequela	10/1/2023
<b>W44.E3XA</b>	Non-magnetic metal toy entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.E3XD</b>	Non-magnetic metal toy entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.E3XS</b>	Non-magnetic metal toy entering into or through a natural orifice, sequela	10/1/2023
<b>W44.E4XA</b>	Non-magnetic metal jewelry entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.E4XD</b>	Non-magnetic metal jewelry entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.E4XS</b>	Non-magnetic metal jewelry entering into or through a natural orifice, sequela	10/1/2023
<b>W44.E9XA</b>	Other non-magnetic metal objects entering into or through a natural orifice, initial encounter	10/1/2023

## SERVICES

<b>W44.E9XD</b>	Other non-magnetic metal objects entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.E9XS</b>	Other non-magnetic metal objects entering into or through a natural orifice, sequela	10/1/2023
<b>W44.F0XA</b>	Objects of natural or organic material unspecified, entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.F0XD</b>	Objects of natural or organic material unspecified, entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.F0XS</b>	Objects of natural or organic material unspecified, entering into or through a natural orifice, sequela	10/1/2023
<b>W44.F1XA</b>	Bezoar entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.F1XD</b>	Bezoar entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.F1XS</b>	Bezoar entering into or through a natural orifice, sequela	10/1/2023
<b>W44.F2XA</b>	Rubber band entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.F2XD</b>	Rubber band entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.F2XS</b>	Rubber band entering into or through a natural orifice, sequela	10/1/2023
<b>W44.F3XA</b>	Food entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.F3XD</b>	Food entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.F3XS</b>	Food entering into or through a natural orifice, sequela	10/1/2023
<b>W44.F4XA</b>	Insect entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.F4XD</b>	Insect entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.F4XS</b>	Insect entering into or through a natural orifice, sequela	10/1/2023
<b>W44.F9XA</b>	Other object of natural or organic material, entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.F9XD</b>	Other object of natural or organic material, entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.F9XS</b>	Other object of natural or organic material, entering into or through a natural orifice, sequela	10/1/2023
<b>W44.G0XA</b>	Other non-organic objects unspecified, entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.G0XD</b>	Other non-organic objects unspecified, entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.G0XS</b>	Other non-organic objects unspecified, entering into or through a natural orifice, sequela	10/1/2023
<b>W44.G1XA</b>	Audio device entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.G1XD</b>	Audio device entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.G1XS</b>	Audio device entering into or through a natural orifice, sequela	10/1/2023
<b>W44.G2XA</b>	Combination metal and plastic toy and toy part entering into or through natural orifice, initial encounter	10/1/2023
<b>W44.G2XD</b>	Combination metal and plastic toy and toy part entering into or through natural orifice, subsequent encounter	10/1/2023
<b>W44.G2XS</b>	Combination metal and plastic toy and toy part entering into or through natural orifice, sequela	10/1/2023
<b>W44.G3XA</b>	Combination metal and plastic jewelry entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.G3XD</b>	Combination metal and plastic jewelry entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.G3XS</b>	Combination metal and plastic jewelry entering into or through a natural orifice, sequela	10/1/2023
<b>W44.G9XA</b>	Other non-organic objects entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.G9XD</b>	Other non-organic objects entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.G9XS</b>	Other non-organic objects entering into or through a natural orifice, sequela	10/1/2023

## SERVICES

<b>W44.H0XA</b>	Other sharp object unspecified, entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.H0XD</b>	Other sharp object unspecified, entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.H0XS</b>	Other sharp object unspecified, entering into or through a natural orifice, sequela	10/1/2023
<b>W44.H1XA</b>	Needle entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.H1XD</b>	Needle entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.H1XS</b>	Needle entering into or through a natural orifice, sequela	10/1/2023
<b>W44.H2XA</b>	Knife, sword or dagger entering into or through a natural orifice, initial encounter	10/1/2023
<b>W44.H2XD</b>	Knife, sword or dagger entering into or through a natural orifice, subsequent encounter	10/1/2023
<b>W44.H2XS</b>	Knife, sword or dagger entering into or through a natural orifice, sequela	10/1/2023
<b>Z02.84</b>	Encounter for child welfare exam	10/1/2023
<b>Z05.81</b>	Observation and evaluation of newborn for suspected condition related to home physiologic monitoring device ruled out	10/1/2023
<b>Z05.89</b>	Observation and evaluation of newborn for other specified suspected condition ruled out	10/1/2023
<b>Z16.13</b>	Resistance to carbapenem	10/1/2023
<b>Z22.340</b>	Carrier of carbapenem-resistant <i>Acinetobacter baumannii</i>	10/1/2023
<b>Z22.341</b>	Carrier of carbapenem-sensitive <i>Acinetobacter baumannii</i>	10/1/2023
<b>Z22.349</b>	Carrier of <i>Acinetobacter baumannii</i> , unspecified	10/1/2023
<b>Z22.350</b>	Carrier of carbapenem-resistant Enterobacterales	10/1/2023
<b>Z22.358</b>	Carrier of other Enterobacterales	10/1/2023
<b>Z22.359</b>	Carrier of Enterobacterales, unspecified	10/1/2023
<b>Z29.81</b>	Encounter for HIV pre-exposure prophylaxis	10/1/2023
<b>Z29.89</b>	Encounter for other specified prophylactic measures	10/1/2023
<b>Z62.23</b>	Child in custody of non-parental relative	10/1/2023
<b>Z62.24</b>	Child in custody of non-relative guardian	10/1/2023
<b>Z62.823</b>	Parent-step child conflict	10/1/2023
<b>Z62.831</b>	Non-parental relative-child conflict	10/1/2023
<b>Z62.832</b>	Non-relative guardian-child conflict	10/1/2023
<b>Z62.833</b>	Group home staff-child conflict	10/1/2023
<b>Z62.892</b>	Runaway [from current living environment]	10/1/2023
<b>Z83.710</b>	Family history of adenomatous and serrated polyps	10/1/2023
<b>Z83.711</b>	Family history of hyperplastic colon polyps	10/1/2023
<b>Z83.718</b>	Other family history of colon polyps	10/1/2023
<b>Z83.719</b>	Family history of colon polyps, unspecified	10/1/2023
<b>Z91.85</b>	Personal history of military service	10/1/2023
<b>Z91.A41</b>	Caregiver's other noncompliance with patient's medication regimen due to financial hardship	10/1/2023



## SERVICES

<b>Z91.A48</b>	Caregiver's other noncompliance with patient's medication regimen for other reason	10/1/2023
<b>Z91.A51</b>	Caregiver's noncompliance with patient's renal dialysis due to financial hardship	10/1/2023
<b>Z91.A58</b>	Caregiver's noncompliance with patient's renal dialysis for other reason	10/1/2023
<b>Z91.A91</b>	Caregiver's noncompliance with patient's other medical treatment and regimen due to financial hardship	10/1/2023
<b>Z91.A98</b>	Caregiver's noncompliance with patient's other medical treatment and regimen for other reason	10/1/2023

[Back to top](#)

Table 4 - ICD-10-PCS Codes

Code	Description	Effective Date
<b>02HW3RZ</b>	Insertion of Short-term External Heart Assist System into Thoracic Aorta, Descending, Percutaneous Approach	10/1/2023
<b>02PW3RZ</b>	Removal of Short-term External Heart Assist System from Thoracic Aorta, Descending, Percutaneous Approach	10/1/2023
<b>02WW3RZ</b>	Revision of Short-term External Heart Assist System in Thoracic Aorta, Descending, Percutaneous Approach	10/1/2023
<b>0CSS0ZZ</b>	Reposition Larynx, Open Approach	10/1/2023
<b>0CSS7ZZ</b>	Reposition Larynx, Via Natural or Artificial Opening	10/1/2023
<b>0CSS8ZZ</b>	Reposition Larynx, Via Natural or Artificial Opening Endoscopic	10/1/2023
<b>0DHI7JZ</b>	Insertion of Magnetic Lengthening Device into Upper Esophagus, Via Natural or Artificial Opening	10/1/2023
<b>0DH27JZ</b>	Insertion of Magnetic Lengthening Device into Middle Esophagus, Via Natural or Artificial Opening	10/1/2023
<b>0DH37JZ</b>	Insertion of Magnetic Lengthening Device into Lower Esophagus, Via Natural or Artificial Opening	10/1/2023
<b>0WHC0GZ</b>	Insertion of Defibrillator Lead into Mediastinum, Open Approach	10/1/2023
<b>0WHC3GZ</b>	Insertion of Defibrillator Lead into Mediastinum, Percutaneous Approach	10/1/2023
<b>0WHC4GZ</b>	Insertion of Defibrillator Lead into Mediastinum, Percutaneous Endoscopic Approach	10/1/2023
<b>0WPC0GZ</b>	Removal of Defibrillator Lead from Mediastinum, Open Approach	10/1/2023
<b>0WPC3GZ</b>	Removal of Defibrillator Lead from Mediastinum, Percutaneous Approach	10/1/2023
<b>0WPC4GZ</b>	Removal of Defibrillator Lead from Mediastinum, Percutaneous Endoscopic Approach	10/1/2023
<b>0WPCXGZ</b>	Removal of Defibrillator Lead from Mediastinum, External Approach	10/1/2023
<b>0WWC0GZ</b>	Revision of Defibrillator Lead in Mediastinum, Open Approach	10/1/2023
<b>0WWC3GZ</b>	Revision of Defibrillator Lead in Mediastinum, Percutaneous Approach	10/1/2023
<b>0WWC4GZ</b>	Revision of Defibrillator Lead in Mediastinum, Percutaneous Endoscopic Approach	10/1/2023
<b>0WWCXGZ</b>	Revision of Defibrillator Lead in Mediastinum, External Approach	10/1/2023
<b>5A09B5K</b>	Assistance with Respiratory Ventilation, Less than 8 Consecutive Hours, Intubated Prone Positioning	10/1/2023
<b>5A09C5K</b>	Assistance with Respiratory Ventilation, 8-24 Consecutive Hours, Intubated Prone Positioning	10/1/2023
<b>5A09D5K</b>	Assistance with Respiratory Ventilation, Greater than 24 Consecutive Hours, Intubated Prone Positioning	10/1/2023
<b>8E0U0EN</b>	Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Open Approach	10/1/2023
<b>8E0U3EN</b>	Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Percutaneous Approach	10/1/2023

## SERVICES

<b>8E0U4EN</b>	Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Percutaneous Endoscopic Approach	10/1/2023
<b>8E0U7EN</b>	Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Via Natural or Artificial Opening	10/1/2023
<b>8E0U8EN</b>	Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Via Natural or Artificial Opening Endoscopic	10/1/2023
<b>8E0W0EN</b>	Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Open Approach	10/1/2023
<b>8E0W3EN</b>	Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Percutaneous Approach	10/1/2023
<b>8E0W4EN</b>	Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Percutaneous Endoscopic Approach	10/1/2023
<b>8E0W7EN</b>	Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Via Natural or Artificial Opening	10/1/2023
<b>8E0W8EN</b>	Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Via Natural or Artificial Opening Endoscopic	10/1/2023
<b>X05I329</b>	Destruction of Renal Sympathetic Nerve(s) using Ultrasound Ablation, Percutaneous Approach, New Technology Group 9	10/1/2023
<b>X2H03R9</b>	Insertion of Intraluminal Device, Bioprosthetic Valve into Inferior Vena Cava, Percutaneous Approach, New Technology Group 9	10/1/2023
<b>X2H13R9</b>	Insertion of Intraluminal Device, Bioprosthetic Valve into Superior Vena Cava, Percutaneous Approach, New Technology Group 9	10/1/2023
<b>X2H20R9</b>	Insertion of Intraluminal Device, Bioprosthetic Valve into Right Femoral Vein, Open Approach, New Technology Group 9	10/1/2023
<b>X2H30R9</b>	Insertion of Intraluminal Device, Bioprosthetic Valve into Left Femoral Vein, Open Approach, New Technology Group 9	10/1/2023
<b>X2H63V9</b>	Insertion of Dual-Chamber Intracardiac Pacemaker into Right Atrium, Percutaneous Approach, New Technology Group 9	10/1/2023
<b>X2HK3V9</b>	Insertion of Dual-Chamber Intracardiac Pacemaker into Right Ventricle, Percutaneous Approach, New Technology Group 9	10/1/2023
<b>X2HL0F9</b>	Insertion of Conduit to Short-term External Heart Assist System into Right Axillary Artery, Open Approach, New Technology Group 9	10/1/2023
<b>X2HM0F9</b>	Insertion of Conduit to Short-term External Heart Assist System into Left Axillary Artery, Open Approach, New Technology Group 9	10/1/2023
<b>X2HX0F9</b>	Insertion of Conduit to Short-term External Heart Assist System into Thoracic Aorta, Ascending, Open Approach, New Technology Group 9	10/1/2023
<b>X2KH3D9</b>	Bypass Right Femoral Artery using Conduit through Femoral Vein to Superficial Femoral Artery, Percutaneous Approach, New Technology Group 9	10/1/2023
<b>X2KH3E9</b>	Bypass Right Femoral Artery using Conduit through Femoral Vein to Popliteal Artery, Percutaneous Approach, New Technology Group 9	10/1/2023

## SERVICES

<b>X2KJ3D9</b>	Bypass Left Femoral Artery using Conduit through Femoral Vein to Superficial Femoral Artery, Percutaneous Approach, New Technology Group 9	10/1/2023
<b>X2KJ3E9</b>	Bypass Left Femoral Artery using Conduit through Femoral Vein to Popliteal Artery, Percutaneous Approach, New Technology Group 9	10/1/2023
<b>X2U4079</b>	Supplement Coronary Artery/Arteries with Vein Graft Extraluminal Support Device(s), Open Approach, New Technology Group 9	10/1/2023
<b>X2UQ0P9</b>	Supplement Right Upper Extremity Vein with Synthetic Substitute, Extraluminal Support Device, Open Approach, New Technology Group 9	10/1/2023
<b>X2UR0P9</b>	Supplement Left Upper Extremity Vein with Synthetic Substitute, Extraluminal Support Device, Open Approach, New Technology Group 9	10/1/2023
<b>XNHG0F9</b>	Insertion of Tibial Extension with Motion Sensors into Right Tibia, Open Approach, New Technology Group 9	10/1/2023
<b>XNHH0F9</b>	Insertion of Tibial Extension with Motion Sensors into Left Tibia, Open Approach, New Technology Group 9	10/1/2023
<b>XNR80D9</b>	Replacement of Skull with Ultrasound Penetrable Synthetic Substitute, Open Approach, New Technology Group 9	10/1/2023
<b>XNRL099</b>	Replacement of Right Tarsal with Talar Prosthesis Synthetic Substitute, Open Approach, New Technology Group 9	10/1/2023
<b>XNRM099</b>	Replacement of Left Tarsal with Talar Prosthesis Synthetic Substitute, Open Approach, New Technology Group 9	10/1/2023
<b>XRJ0B9</b>	Fusion of Right Ankle Joint using Open-truss Design Internal Fixation Device, Open Approach, New Technology Group 9	10/1/2023
<b>XRK0B9</b>	Fusion of Left Ankle Joint using Open-truss Design Internal Fixation Device, Open Approach, New Technology Group 9	10/1/2023
<b>XRGL0B9</b>	Fusion of Right Tarsal Joint using Open-truss Design Internal Fixation Device, Open Approach, New Technology Group 9	10/1/2023
<b>XRGM0B9</b>	Fusion of Left Tarsal Joint using Open-truss Design Internal Fixation Device, Open Approach, New Technology Group 9	10/1/2023
<b>XW013L9</b>	Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9	10/1/2023
<b>XW013S9</b>	Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9	10/1/2023
<b>XW033K9</b>	Introduction of Sulbactam-Durlobactam into Peripheral Vein, Percutaneous Approach, New Technology Group 9	10/1/2023
<b>XW033P9</b>	Introduction of Glofitamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 9	10/1/2023
<b>XW033Q9</b>	Introduction of Posoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 9	10/1/2023
<b>XW033R9</b>	Introduction of Rezafungin into Peripheral Vein, Percutaneous Approach, New Technology Group 9	10/1/2023
<b>XW043K9</b>	Introduction of Sulbactam-Durlobactam into Central Vein, Percutaneous Approach, New Technology Group 9	10/1/2023
<b>XW043P9</b>	Introduction of Glofitamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 9	10/1/2023
<b>XW043Q9</b>	Introduction of Posoleucel into Central Vein, Percutaneous Approach, New Technology Group 9	10/1/2023
<b>XW043R9</b>	Introduction of Rezafungin into Central Vein, Percutaneous Approach, New Technology Group 9	10/1/2023

## SERVICES

<b>XW053T9</b>	Introduction of Melphalan Hydrochloride Antineoplastic into Peripheral Artery, Percutaneous Approach, New Technology Group 9	10/1/2023
<b>XW0DXJ9</b>	Introduction of Quizartinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 9	10/1/2023
<b>XW0DXN9</b>	Introduction of SER-109 into Mouth and Pharynx, External Approach, New Technology Group 9	10/1/2023
<b>XWI33H9</b>	Transfusion of Lovotibeglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 9	10/1/2023
<b>XWI43H9</b>	Transfusion of Lovotibeglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 9	10/1/2023
<b>XX20X89</b>	Monitoring of Brain Electrical Activity, Computer-aided Detection and Notification, New Technology Group 9	10/1/2023
<b>XX2F3W9</b>	Monitoring of Musculoskeletal Muscle Compartment Pressure, Micro-Electro-Mechanical System, Percutaneous Approach, New Technology Group 9	10/1/2023
<b>XXE2X19</b>	Measurement of Cardiac Output, Computer-aided Assessment, New Technology Group 9	10/1/2023
<b>XXE5XY9</b>	Measurement of Infection, Other Positive Blood/Isolated Colonies Bimodal Phenotypic Susceptibility Technology, New Technology Group 9	10/1/2023

[Back to top](#)

Table 5 – Modifiers

Modifier	Description	Effective Date
N/A	N/A	N/A

[Back to top](#)

Table 6 – Outpatient Hospital

Code	Description	Effective Date
<b>0408U</b>	Infectious agent antigen detection by bulk acoustic wave biosensor immunoassay, severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19])	10/1/2023
<b>A9573</b>	Injection, gadopiclesol, 1 ml	10/1/2023
<b>A9603</b>	Injection, pafolacianine, 0.1 mg	10/1/2023
<b>A9697</b>	Injection, carboxydextran-coated superparamagnetic iron oxide, per study dose	10/1/2023
<b>C9152</b>	Injection, aripiprazole, (abilify asimtufii), 1 mg	10/1/2023
<b>C9153</b>	Injection, amisulpride, 1 mg	10/1/2023
<b>C9154</b>	Injection, buprenorphine extended-release (brixadi), 1 mg	10/1/2023
<b>C9155</b>	Injection, epcoritamab-bysp, 0.16 mg	10/1/2023
<b>C9156</b>	Flotufolastat f 18, diagnostic, 1 millicurie	10/1/2023
<b>C9157</b>	Injection, tofersen, 1 mg	10/1/2023
<b>C9158</b>	Injection, risperidone, (uzedy), 1 mg	10/1/2023
<b>C9791</b>	Magnetic resonance imaging with inhaled hyperpolarized xenon-129 contrast agent, chest, including preparation and administration of agent	10/1/2023

## SERVICES

<b>H2040</b>	Coordinated specialty care, team-based, for first episode psychosis, per month	10/1/2023
<b>H2041</b>	Coordinated specialty care, team-based, for first episode psychosis, per encounter	10/1/2023
<b>J0349</b>	Injection, rezafungin, 1 mg	10/1/2023
<b>J0801</b>	Injection, corticotropin (acthar gel), up to 40 units	10/1/2023
<b>J0802</b>	Injection, corticotropin (ani), up to 40 units	10/1/2023
<b>J0874</b>	Injection, daptomycin (baxter), not therapeutically equivalent to j0878, 1 mg	10/1/2023
<b>J0889</b>	Daprodustat, oral, 1 mg, (for esrd on dialysis)	10/1/2023
<b>J2359</b>	Injection, olanzapine, 0.5 mg	10/1/2023
<b>J2781</b>	Injection, pegcetacoplan, intravitreal, 1 mg	10/1/2023
<b>J7214</b>	Injection, factor viii/von willebrand factor complex, recombinant (altuviio), per factor viii i.u.	10/1/2023
<b>J7519</b>	Injection, mycophenolate mofetil, 10 mg	10/1/2023
<b>J9064</b>	Injection, cabazitaxel (sandoz), not therapeutically equivalent to j9043, 1 mg	10/1/2023
<b>J9345</b>	Injection, retifanlimab-dlwr, 1 mg	10/1/2023

[Back to top](#)**Table 8 – Non-covered codes**

Code	Desc
<b>0019M</b>	Cardiovascular disease, plasma, analysis of protein biomarkers by aptamer-based microarray and algorithm reported as 4-year likelihood of coronary event in high-risk populations
<b>0402U</b>	Infectious agent (STI), Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium, multiplex amplified probe technique, vaginal, endocervical, or male urine, each Pathogen
<b>0403U</b>	Oncology (prostate), mRNA, gene expression profiling of 18 genes, first-catch post-digital rectal examination urine, algorithm reported as percentage of likelihood of detecting clinically significant prostate cancer
<b>0404U</b>	Oncology (breast), semiquantitative measurement of thymidine kinase activity by immunoassay, serum, results reported as risk of disease progression
<b>0405U</b>	Oncology (pancreatic), 59 methylation haplotype block markers, next-generation sequencing, plasma, reported as cancer signal detected or not detected
<b>0406U</b>	Oncology (lung), flow cytometry, sputum, 5 markers (meso-tetra [4-carboxyphenyl] porphyrin [TCPP], CD206, CD66b, CD3, CD19), algorithm reported as likelihood of lung cancer
<b>0407U</b>	Nephrology (diabetic chronic kidney disease), multiplex electrochemiluminescent immunoassay of soluble tumor necrosis factor receptor 1, soluble tumor necrosis receptor 2, & kidney injury molecule 1 combined w/ clinical data
<b>0409U</b>	Oncology (solid tumor), DNA (80 genes) and RNA (36 genes), by next-generation sequencing from plasma, including single nucleotide variants, insertions/deletions, copy number alterations, microsatellite instability, & fusions
<b>0410U</b>	Oncology (pancreatic), DNA, whole genome sequencing with 5-hydroxymethylcytosine enrichment, whole blood or plasma, algorithm reported as cancer detected or not detected

## SERVICES

<b>0411U</b>	Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6
<b>0412U</b>	Beta amyloid, AB42/40 ratio, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and qualitative ApoE isoform-specific proteotyping, plasma combined with age
<b>0413U</b>	Oncology (hematolymphoid neoplasm), optical genome mapping for copy number alterations, aneuploidy, and balanced/complex structural rearrangements, DNA from blood or bone marrow, report of clinically significant alterations
<b>0414U</b>	Oncology (lung), augmentative algorithmic analysis of digitized whole slide imaging for 8 genes (ALK, BRAF, EGFR, ERBB2, MET, NTRK1-3, RET, ROS1), & KRAS G12C and PD-L1, if performed, formalin-fixed paraffin-embedded tissue
<b>0415U</b>	Cardiovascular disease (acute coronary syndrome), IL-16, FAS, FASLigand, HGF, CTACK, EOTAXIN & MCP-3 by immunoassay combined w/ age, sex, family history, & personal hx of diabetes, blood, algorithm reported as a 5-year score
<b>0416U</b>	Infectious agent detection by nucleic acid (DNA), genitourinary pathogens, identification of 20 bacterial & fungal organisms, including identification of 20 associated atb-resistance genes, if performed
<b>0417U</b>	Rare diseases (constitutional/heritable disorders), whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis, nuclear-encoded mitochondrial gene analysis of 335 nuclear genes
<b>0418U</b>	Oncology (breast), augmentative algorithmic analysis of digitized whole slide imaging of 8 histologic and immunohistochemical features, reported as a recurrence score
<b>0419U</b>	Neuropsychiatry (eg, depression, anxiety), genomic sequence analysis panel, variant analysis of 13 genes, saliva or buccal swab, report of each gene phenotype
<b>A2022</b>	Innovaburn or innovamatrix xl, per square centimeter
<b>A2023</b>	Innovamatrix pd, 1 mg
<b>A2024</b>	Resolve matrix, per square centimeter
<b>A2025</b>	Miro3d, per cubic centimeter
<b>A9156</b>	Oral mucoadhesive, any type (liquid, gel, paste, etc.), per 1 ml
<b>A9268</b>	Programmer for transient, orally ingested capsule
<b>A9269</b>	Programable, transient, orally ingested capsule, for use with external programmer, per month
<b>A9292</b>	Prescription digital visual therapy, software-only, fda cleared, per course of treatment
<b>C9788</b>	Opto-acoustic imaging, breast (including axilla when performed), unilateral, with image documentation, analysis and report, obtained with ultrasound examination
<b>C9789</b>	Instillation of anti-neoplastic pharmacologic/biologic agent into renal pelvis, any method, including all imaging guidance, including volumetric measurement if performed
<b>C9790</b>	Histotripsy (ie, non-thermal ablation via acoustic energy delivery) of malignant renal tissue, including image guidance
<b>C9792</b>	Blinded or nonblinded procedure for symptomatic new york heart association class ii, iii, iva heart failure; transcath implantation of lt atrial to coronary sinus shunt using jugular vein access, including all imaging
<b>E0490</b>	Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by hardware remote

## SERVICES

<b>E0491</b>	Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by hardware remote, 90-day supply
<b>H2040</b>	Coordinated specialty care, team-based, for first episode psychosis, per month
<b>H2041</b>	Coordinated specialty care, team-based, for first episode psychosis, per encounter
<b>J7353</b>	Anacaulase-bcdb, 8.8% gel, 1 gram
<b>J9051</b>	Injection, bortezomib (maia), not therapeutically equivalent to j9041, 0.1 mg
<b>K1036</b>	Supplies and accessories (e.g., transducer) for low frequency ultrasonic diathermy treatment device, per month
<b>L5991</b>	Addition to lower extremity prostheses, osseointegrated external prosthetic connector
<b>Q4285</b>	Nudyn dl or nudyn dl mesh, per square centimeter
<b>Q4286</b>	Nudyn sl or nudyn slw, per square centimeter
<b>V2526</b>	Contact lens, hydrophilic, with blue-violet filter, per lens

[Back to top](#)**Table 9 – Deleted Codes**

Code	Desc	Effective Date	Replacement Code (if applicable)
<b>0066U</b>	Placental alpha-micro globulin-I (PAMG-I), immunoassay with direct optical observation, cervico-vaginal fluid, each specimen	9/30/2023	
<b>0357U</b>	Oncology (melanoma), artificial intelligence (AI)-enabled quantitative mass spectrometry analysis of 142 unique pairs of glycopeptide and product fragments, plasma, prognostic, and predictive algorithm reported as likely, unlikely, or uncertain benefit from immunotherapy agents	9/30/2023	
<b>0386U</b>	Gastroenterology (Barrett's esophagus), PI6, RUNX3, HPPI, and FBNI methylation analysis, prognostic and predictive algorithm reported as a risk score for progression to high-grade dysplasia or esophageal cancer	9/30/2023	
<b>0397U</b>	Oncology (non-small cell lung cancer), cell-free DNA from plasma, targeted sequence analysis of at least 109 genes, including sequence variants, substitutions, insertions, deletions, select rearrangements, and copy number variations	9/30/2023	
<b>C9151</b>	Injection, pegcetacoplan, 1 mg	9/30/2023	J2781
<b>J0800</b>	Injection, corticotropin, up to 40 units	9/30/2023	

[Back to top](#)